Cancer Therapy: Monoclonal Antibodies, Lymphokines. New Developments in Surgical Oncology and Chemo- And Hormonal Therapy
A variety of new cancer therapy modalities are discussed and evaluated in this book. It aims to demonstrate that the combination of classical chemo- and radiotherapy with new approaches in the field of immunotherapy can result in an improved treatment modality. Immunotherapy in this context consists of therapy with monoclonal antibodies, hematopoietic growth factors and other lymphokines. Results of early clinical trials with IL-2, GM-CSF and monoclonal antibodies against gastrointestinal tumors and melanoma are included. The progress in regional chemotherapy strategies, for example of the liver, is shown. In addition, the development of new chemotherapeutic agents with a different mode of action as well as better tolerability is presented. The use of hormones, such as LH-RH agonists, allows hormone-dependent tumors such as prostatic and breast cancer to be treated without strong adverse reactions. These recent findings give the reader insight into exciting therapeutic directions made possible by such combined, rather than single, modalities.
What people are saying - Write a review
We haven't found any reviews in the usual places.
R A REISFELD B MULLER and H M YANG
H KALOFONOS and A A EPENETOS
BUCHLER R KOBEL R KLAPDOR K H MUHRER
16 other sections not shown
Other editions - View all
5-fluorouracil activity adjuvant administration adriamycin aminoglutethimide anthracycline anti antitumor assay Berlin Heidelberg bone marrow breast cancer Cancer Res Caneer Therapy carcinoembryonic antigen cardiotoxicity catheter chemo chemoembolization Clin Oncol colon colony-stimulating factor colorectal cancer colorectal carcinoma combination concentrations cytokines Cytorhodin cytostatic cytotoxic disease dose doxorubicin drug evaluation extrahepatic FUDR ganglioside GM-CSF granulocytes growth H.G. Beger hairy cell leukemia hepatic arterial infusion hormone human tumor immunotherapy increase induced inhibition interferon interleukin-2 intra-arterial intrahepatic Klapdor levels LHRHA liver metastases lymph node lymphocytes MAb BW median survival mitomycin monoclonal antibodies monocytes months neutrophils normal nude mice Oncology pancreatic carcinoma patients treated perfusion phase Pirarubicin Proc pump radiolabeled receptor recombinant regional chemotherapy resection response rate rhGM-CSF serum side effects Springer-Verlag Berlin surgery surgical systemic Table therapeutic tion tissue toxicity treatment tumor cells uptake vitro vivo xenografts